Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
A new study just published in the Canadian Journal of Urology has reminded us of the importance of the digital rectal emamination (DRE) in the initial diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, digital, DRE, examination, rectal | 5 Comments »
Until very recently, all available guidelines for the early assessment of risk for prostate cancer clearly recommended the use of a physical examination (a digital rectal exam or DRE) in addition to a prostate-specific antigen (PSA) test. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: digital rectal examination, DRE, guideline, PSA, risk | 1 Comment »
A new report just published as an open access, full-text article at BMJ.com is going to further confuse the issue of whether mass, population-based screening for prostate cancer is or isn’t a good idea. … READ MORE …
Filed under: Diagnosis, Risk, Uncategorized | Tagged: DRE, mortality, Norrkoping, outcome, PSA, screening, Sweden | 14 Comments »
A new review by specialists from Erasmus University Medical Center, just published in Prostate Cancer and Prostatic Diseases, states categorically that mass, population-based screening for prostate cancer “cannot be justified yet in the context of a public health policy.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: DRE, population-based, PSA, risk, screening | 22 Comments »
A new article in the Australian Medical Journal is titled, “It’s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials.” We think this article makes a lot of sense. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, screening, testing | 1 Comment »
In today’s news reports we cover items on:
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: adipose, blood loss, BMI, body mass index, DRE, ethnicity, recurrence, religion, risk, smoking | Leave a Comment »
This morning’s news reports address:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, DRE, LHRH agonist, mechanism of action, pattens of use, PSA | Leave a Comment »
Even though many medical organizations recommend discussions between patients and their doctors before testing of individuals for risk of prostate cancer, there are few hard data about how primary care physicians (PCPs) actually apply thee guidelines to promote informed decision making for prostate cancer testing. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: DRE, PCP, primary care physician, PSA, screening, testing | Leave a Comment »
… a paper from the University of Texas Health Sciences Center in San Antonio has provided a detailed analysis of the spectrum of variation of PSA and DRE data among men in an earlier screening program. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: changes over time, DRE, PSA, screening | 3 Comments »
Many readers may be interested in seeing what Johns Hopkins has to say about the two studies published just over a week ago in the New England Journal of Medicine.
This topic is addressed under the heading “Recent PSA Studies: What You Need To Know” in the latest issue of Health Alerts. Interestingly, in this article, Dr. H. Ballentine Carter seems to come down fairly firmly in the same camp as editorialist Michael J. Barry, MD, in his comments on these studies in the New England Journal of Medicine itself.
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, risk, screening | 1 Comment »
We thought it might be wise to make sure that readers of The “New” Prostate Cancer InfoLink didn’t just hear what we thought about today’s two NEJM articles, but also got a cross-section of perspectives from others.
Where relevant we have taken the liberty of giving our opinion on the articles we think you might like to look at, but we have tried hard not to pick articles that necessarily agree with us. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, screening | 1 Comment »
As we have already, albeit briefly, reported, two “major” papers were published in the New England Journal of Medicine today, and they both were designed to address the appropriateness of mass screening for prostate cancer — among men over the age of 55 years in the USA and over 50 years in Europe respectively.
We wish to state two things immediately:
Filed under: Diagnosis, Risk | Tagged: DRE, PSA, randomized trial, screening | 11 Comments »
There are six reports in the news for the weekend, addressing such topics as:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3D transrectal ultrasound, baldness, biopsy, colonoscopy, DRE, gynecomastia, Sendai virus | Leave a Comment »
Today’s news reports are focused on issued around epidemiology, prevention, diagnosis, treatment decisions, and the role of humor in prostate cancer support group interactions. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active surveillance, arsenic, DRE, finasteride, humor, masculinity, Prevention, support groups | Leave a Comment »
Today’s reports include items on:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: castration, DRE, hemi-body radiation, orchiectomy, stage T3 disease | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site